The SGLT2 inhibitor empagliflozin does not stimulate compensatory appetite responses in patients with excess adiposity and type 2 diabetes
conference contribution
posted on 2020-10-13, 09:43 authored by Melanie J Davies, Emma L Baldry, Danielle H Bodicoat, S Chatterjee, Charlotte L Edwardson, Laura J Gray, Kamlesh Khunti, Jack A Sargeant, David J Stensel, David R Webb, John P H Wilding, Scott A Willis, Tom Yates, James A KingConference abstract
Funding
Boehringer Ingelheim and supported in-kind by the NIHR Leicester BRC
History
Citation
Diabetologia 63, 1–485 (2020). https://doi.org/10.1007/s00125-020-05221-5Author affiliation
Diabetes Research Centre, College of Life SciencesSource
56th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD)Version
- AM (Accepted Manuscript)
Published in
DIABETOLOGIAVolume
63Issue
SUPPL 1Pagination
S116 - S116Publisher
Springerissn
0012-186Xeissn
1432-0428Copyright date
2020Available date
2021-08-25Publisher DOI
Spatial coverage
ELECTR NETWORKTemporal coverage: start date
2020-09-21Temporal coverage: end date
2020-09-25Language
enPublisher version
Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC